What are the potential harms of using beta-blockers in patients with peripheral arterial disease (PAD)?
Most of the trials were over 10 years old, reported on between 1980 and 1991. All were small and of poor quality. The drugs were administered for a short period of time (10 days to 2 months) and most of the outcome measures were reported in single studies. Additional drugs, calcium channel blockers and combined alpha and beta-blockers, were also given in some of the trials.
Beta-blockers have been shown to decrease mortality in people with high blood pressure and coronary artery disease. Optimal therapy for people with either coronary artery disease or hypertension and PAD is controversial. This is because of the presumed peripheral blood flow consequences of beta-blockers, leading to worsening of symptoms.